Nilai Buku saben Saham: COSCIENS Biopharma (CSCI)

COSCIENS Biopharma Inc. (CSCI) minimizes risks through the diversity of trial stages for orphan drugs in the US and Europe. A focus on rare endocrine and oncological pathologies provides the company with an exclusive market niche. The book value per share reflects the dynamics of net assets, and its value has stabilized at 1.65. Stable raw material flows and warehouse reserves guarantee uninterrupted logistics.

Aeterna Zentaris - Aset Bersih saben Saham CSCI (periode 10.08.2024 - 14.09.2025)

Ringkesan rincian data analitis cosciensbio.com (CSCI)

- rega lan prakiraan konsensus rega:

Rega saham Aeterna Zentaris|CSCI - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar COSCIENS Biopharma Inc.|CSCI - Rega Tumbas Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham COSCIENS Biopharma|CSCI - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku cosciensbio.com|CSCI - Nilai Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal COSCIENS Biopharma Inc.|CSCI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal COSCIENS Biopharma|CSCI - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku COSCIENS Biopharma Inc.

Analisis kabeh metrik perusahaan:Aeterna Zentaris CSCI

Book value measures a company's net assets minus all liabilities, determining the actual value of the shareholder's equity stake. By analyzing the book value per share, an investor can see the fundamental basis of COSCIENS Biopharma Inc. (CSCI), which is built through capital-intensive R&D investments in patents and strict adherence to FDA regulatory standards during the development of biologics.

Pesaing COSCIENS Biopharma Inc. (CSCI)